![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » GlaxoSmithKline, CureVac Join Forces on mRNA Vaccine Effort
GlaxoSmithKline, CureVac Join Forces on mRNA Vaccine Effort
July 21, 2020
GlaxoSmithKline (GSK) and CureVac have entered a strategic collaboration for research and commercialization of five messenger RNA-based vaccines and monoclonal antibodies for infectious diseases.
GSK will make a $164 million investment in CureVac, representing a 10 percent stake in the company, as well as make a $131 million upfront payment. GSK will also make a one-time reimbursable payment of $32 million to reserve manufacturing capacity.
CureVac’s existing mRNA-based COVID-19 vaccine program is not included in this collaboration.
Upcoming Events
-
21Oct